Gsk (GSK) Tax Provisions (2009 - 2026)
Gsk (GSK) posted quarterly Tax Provisions of $267.0 million for Q2 2026, up 183.05% year-over-year from $94.3 million in Q2 2025, and up 164.93% quarter-over-quarter from -$411.2 million in Q1 2026.
Gsk (GSK) Tax Provisions (2009 - 2026) Analysis & Trends
Gsk's Tax Provisions history runs 18 years deep, the most recent figure standing at $267.0 million for Q2 2026.
- In Q2 2026, Tax Provisions rose 183.05% year-over-year to $267.0 million; the TTM figure through Jun 2026 stood at -$2.0 billion (down 44.12% YoY), while the FY2025 annual figure was $1.5 billion, up 118.06% from the prior year.
- Tax Provisions for Q2 2026 stood at $267.0 million, up from -$411.2 million in the prior quarter.
- The five-year high for Tax Provisions was $347.6 million in Q1 2024, with the low at -$1.5 billion in Q4 2025.
- The 5-year median for Tax Provisions is -$323.5 million (2023), against an average of -$350.8 million.
- The sharpest annual moves came in 2025 and 2026: Tax Provisions plunged 32502.13% in 2025, then surged 183.05% in 2026.
- Gsk's Tax Provisions stood at -$829.3 million in 2022, then decreased by 13.15% to -$938.3 million in 2023, then rose by 28.05% to -$675.1 million in 2024, then sank by 119.09% to -$1.5 billion in 2025, then surged by 118.05% to $267.0 million in 2026.
- Business Quant data shows GSK's Tax Provisions at $267.0 million in Q2 2026, -$411.2 million in Q1 2026, and -$1.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 266.99 Mn |
| Mar 31, 2026 | -411.19 Mn |
| Dec 31, 2025 | -1.48 Bn |
| Sep 30, 2025 | -421.00 Mn |
| Jun 30, 2025 | -321.51 Mn |
| Mar 31, 2025 | -423.19 Mn |
| Dec 31, 2024 | -675.12 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | -241.08 Mn |
| Mar 31, 2024 | 347.57 Mn |
| Dec 31, 2023 | -938.31 Mn |
| Sep 30, 2023 | -325.54 Mn |
| Jun 30, 2023 | -302.83 Mn |
| Mar 31, 2023 | 335.48 Mn |
| Dec 31, 2022 | -829.26 Mn |
| Sep 30, 2022 | -274.60 Mn |
| Jun 30, 2022 | -188.90 Mn |
| Mar 31, 2022 | -433.41 Mn |
| Dec 31, 2021 | 157.72 Mn |
| Sep 30, 2021 | -339.13 Mn |